HMS Capital Management’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q1
Sell
-2,538
Closed -$218K 116
2024
Q4
$218K Sell
2,538
-52
-2% -$5.62K 0.11% 106
2024
Q3
$308K Sell
2,590
-13
-0.5% -$1.73K 0.15% 92
2024
Q2
$371K Sell
2,603
-25
-1% -$3.31K 0.19% 87
2024
Q1
$337K Sell
2,628
-709
-21% -$84.4K 0.19% 87
2023
Q4
$345K Hold
3,337
0.21% 87
2023
Q3
$303K Sell
3,337
-149
-4% -$13.1K 0.2% 92
2023
Q2
$282K Buy
3,486
+30
+0.9% +$2.45K 0.17% 99
2023
Q1
$275K Buy
+3,456
New +$245K 0.17% 93

Other funds holding NVO

HMS Capital Management's NVO Position: Q1 2025 in Review

HMS Capital Management sold out of Novo Nordisk (NVO) in Q1 2025, closing a stake of 2,538 shares — an estimated $218K sold.

HMS Capital Management first reported a position in NVO in Q1 2023 and held it in 8 quarters. The position peaked at $371K in Q2 2024. 1,528 funds tracked by Wall St. Rank hold NVO as of Q1 2025.

  • HMS Capital Management reported no remaining Novo Nordisk position as of Q1 2025 after selling out during the quarter.
  • HMS Capital Management sold 2,538 Novo Nordisk shares in Q1 2025, an estimated $218K.
  • HMS Capital Management first reported a position in Novo Nordisk in Q1 2023 and held it in 8 quarters.
  • HMS Capital Management's Novo Nordisk position peaked at $371K in Q2 2024.
  • 1,528 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2025.

Based on HMS Capital Management's 13F filing for Q1 2025, filed 14 May 2025.